Last updated: October 4, 2026
Serzone, the former brand name for nefazodone, moved from a commercially significant antidepressant to a largely discontinued product after reports of severe liver injury. Bristol-Myers Squibb launched Serzone in the United States in 1994, but the company discontinued U.S. sales in 2004 after regulatory warnings and declining demand. Generic nefazodone remains available in limited markets and through restricted channels, but it has no meaningful branded market position.
The commercial decline resulted from safety risk rather than direct loss of patent exclusivity. Nefazodone competed in the serotonin reuptake inhibitor market but lost prescriber confidence after the FDA identified rare cases of life-threatening hepatic failure. Its financial trajectory followed a sharp pattern: launch growth, antidepressant-market expansion, safety-driven contraction, brand withdrawal, and residual generic demand.
What is Serzone and who marketed nefazodone?
Serzone is the former U.S. brand for nefazodone hydrochloride, an oral antidepressant approved for major depressive disorder. Bristol-Myers Squibb developed and marketed the product in the United States.
| Product attribute |
Serzone / nefazodone |
| Active ingredient |
Nefazodone hydrochloride |
| Drug class |
Serotonin antagonist and reuptake inhibitor |
| Original sponsor |
Bristol-Myers Squibb |
| U.S. approval |
1994 |
| Primary indication |
Major depressive disorder |
| Dosage form |
Immediate-release oral tablets |
| U.S. brand status |
Discontinued in 2004 |
| Main commercial issue |
Severe hepatotoxicity and acute liver-failure risk |
| Current U.S. market |
Generic and limited availability |
| Biosimilar relevance |
None; nefazodone is a small-molecule drug |
Nefazodone acts through serotonin receptor antagonism and inhibition of serotonin and norepinephrine reuptake. It was positioned as an alternative to selective serotonin reuptake inhibitors, particularly for patients concerned about sexual dysfunction or insomnia associated with other antidepressants.
How did Serzone’s sales change over time?
Serzone’s sales rose during the 1990s as the antidepressant market expanded and physicians adopted alternatives to older tricyclic antidepressants. Public company filings and contemporary market reports placed annual U.S. sales in the hundreds of millions of dollars before the safety crisis. Exact peak-sales figures vary by reporting period and whether international sales are included.
| Period |
Commercial development |
Financial effect |
| 1994-1996 |
U.S. launch and initial adoption |
Revenue growth from branded prescriptions |
| 1997-1999 |
Broader antidepressant use and expanded physician familiarity |
Peak or near-peak commercial period |
| 2000 |
First major hepatotoxicity warnings and label changes |
Prescribing pressure increased |
| 2001-2002 |
FDA black-box warning and heightened monitoring concerns |
Rapid erosion in prescriptions and revenue |
| 2003 |
Bristol-Myers Squibb announced plans to discontinue U.S. marketing |
Brand value declined sharply |
| 2004 |
U.S. commercial withdrawal completed |
Branded revenue effectively ended |
| 2005 onward |
Generic nefazodone remained in limited supply |
Residual low-value market |
Bristol-Myers Squibb’s decision was commercially rational because safety warnings reduced the addressable patient population, increased physician liability concerns, and made the product less attractive relative to antidepressants with broader prescribing acceptance. The brand lost value before its full commercial withdrawal because the FDA warning changed the risk-benefit calculation for new prescriptions and refills.
What caused Serzone’s revenue decline?
The principal driver was hepatotoxicity. Reports linked nefazodone to severe liver injury, including cases requiring transplantation and cases resulting in death. The FDA required stronger warnings and later added a boxed warning concerning potentially life-threatening hepatic failure.[1]
The risk was rare, but its severity was commercially decisive. Antidepressants are chronic-use products prescribed to large patient populations. A rare event with a fatal outcome can materially alter prescribing even when the absolute incidence is low. Physicians could select competing products without the same prominent liver-failure warning, which weakened Serzone’s market position.
When did Serzone lose exclusivity and when was it withdrawn?
Serzone’s effective commercial exclusivity ended before or around the period when generic nefazodone became available. The precise patent chronology is less important to current market analysis than the safety-driven collapse of branded demand.
| Event |
Date or period |
| U.S. FDA approval |
1994 |
| FDA hepatotoxicity warning activity |
2000-2001 |
| Boxed warning added |
2001 |
| Bristol-Myers Squibb U.S. discontinuation announcement |
2003 |
| U.S. brand withdrawal |
2004 |
| Generic nefazodone availability |
Early 2000s, with later supply limitations |
Bristol-Myers Squibb stated that it would discontinue Serzone in the United States because of declining sales, not because the FDA formally required removal from the market.[2] The company continued to communicate that generic nefazodone could remain available.
What patents protected Serzone and nefazodone?
The original nefazodone patent estate is no longer commercially controlling in the United States. Any primary composition or formulation patents associated with the original development period have expired or ceased to create a practical barrier to generic competition.
| Patent category |
Current commercial position |
| Active ingredient or composition patents |
Expired or no longer commercially relevant |
| Original tablet formulations |
Expired or no longer commercially relevant |
| Method-of-use patents |
No known active U.S. exclusivity affecting current access |
| Pediatric exclusivity |
Not a current market barrier |
| Orphan-drug exclusivity |
Not applicable |
| U.S. regulatory exclusivity |
Expired |
| Biosimilar exclusivity |
Not applicable |
The U.S. Food and Drug Administration’s Orange Book is the relevant source for approved drug patents and exclusivity listings. Serzone’s commercial withdrawal and the availability of generic nefazodone indicate that patent protection is not the principal barrier to market entry.[3]
Are formulation patents still relevant to nefazodone?
Formulation patents do not appear to create a meaningful current barrier for conventional nefazodone tablets. The marketed product was an immediate-release oral formulation rather than a complex delivery system, long-acting injectable, inhaled product, or biologic.
The principal technical barriers are manufacturing and supply economics. These include low market volume, limited commercial incentive, active-pharmaceutical-ingredient sourcing, quality-control requirements, and the cost of maintaining an FDA-approved product for a small patient population.
Are method-of-use patents relevant to Serzone?
Method-of-use patents are not a material source of current market exclusivity for nefazodone. The original approved use was major depressive disorder, a broad indication for which any historic protection has expired. No active branded method-of-use strategy has reshaped the market.
What is the FDA regulatory status of Serzone?
Serzone is not an actively marketed U.S. brand. Nefazodone remains an FDA-approved active ingredient in generic form, but its use is constrained by the boxed warning for potentially life-threatening liver failure.
The FDA-approved labeling warns against use in patients with active liver disease or elevated baseline serum transaminases. The label also requires discontinuation if clinical signs or symptoms of liver injury develop.[4]
What is the Serzone boxed warning?
The boxed warning states that cases of life-threatening hepatic failure have been reported in patients treated with nefazodone. The label identifies an estimated incidence of approximately one case of liver failure resulting in death or transplantation for every 250,000 to 300,000 patient-years of treatment, although the FDA emphasizes that the true rate may differ because of reporting limitations.[4]
The warning sharply reduced the product’s commercial utility. Physicians must weigh the risk against alternatives that are available for the same indication, including SSRIs, SNRIs, atypical antidepressants, and other agents.
What is the Orange Book status of Serzone?
Serzone has no meaningful active branded Orange Book position because the brand was withdrawn from U.S. commerce. Generic nefazodone products may have abbreviated new drug application listings, but those listings do not restore the original brand’s market power.
| Orange Book issue |
Assessment |
| Active Serzone brand listing |
No meaningful commercial status |
| Listed brand patents |
No active exclusivity controlling current entry |
| Generic ANDAs |
Historically available |
| Paragraph IV activity |
Not a current commercial driver |
| Therapeutic-equivalence relevance |
Applies to approved generic products, subject to availability |
| Current litigation value |
Minimal |
Which companies challenged Serzone patents?
Generic manufacturers entered the nefazodone market after the product’s principal commercial protection had eroded. The relevant competitive activity was generic entry rather than a prolonged, high-value patent challenge involving an active blockbuster franchise.
Publicly documented Serzone litigation did not produce a current patent barrier comparable with major small-molecule products that face repeated Paragraph IV challenges. Any historic Paragraph IV certifications would have related to the timing of generic approval and patent expiry. They do not provide a present-day basis for delaying nefazodone access.
What litigation affected Serzone?
The important legal exposure involved product-liability claims and regulatory risk associated with liver injury, rather than a continuing patent dispute.
The hepatotoxicity issue generated substantial litigation exposure because plaintiffs alleged severe injury, liver transplantation, or death after use of nefazodone. The safety controversy also affected the commercial value of the brand and the economics of continued promotion.
| Litigation or regulatory issue |
Business effect |
| Hepatic failure claims |
Increased liability exposure |
| Failure-to-warn allegations |
Greater litigation and settlement risk |
| FDA labeling action |
Reduced prescribing |
| Generic competition |
Lower price and lower brand leverage |
| Patent litigation |
Limited present relevance |
No major active patent settlement agreement currently determines generic entry for nefazodone. The product’s commercial history is primarily a safety and liability case, not a patent-extension case.
How strong is the Serzone patent estate?
The current Serzone patent estate is weak. The product has no credible active composition, formulation, method-of-use, or regulatory exclusivity that would support premium pricing or restrict generic competition.
Patent strength can be assessed across five dimensions:
| Patent-strength factor |
Assessment |
| Remaining term |
No meaningful remaining term for original protection |
| Claim breadth |
Historic claims no longer commercially controlling |
| Generic design-around risk |
Low relevance because generic entry already occurred |
| Litigation leverage |
Low |
| Revenue protection |
None for the discontinued brand |
The more important barrier is not intellectual property. It is the small and medically constrained market created by the boxed warning.
What generic entry risks exist for nefazodone?
Generic entry risk is high in legal terms but mixed in commercial terms. The absence of meaningful patent protection permits entry, but the market is unattractive to many manufacturers because demand is limited and supply obligations can exceed expected revenue.
Generic manufacturers face several commercial issues:
- Low prescription volume after the brand withdrawal.
- A warning profile that limits physician adoption.
- Potential product-liability exposure.
- Manufacturing costs that may not be supported by market size.
- Supply-chain vulnerability if only a small number of manufacturers remain.
- Limited opportunity to differentiate a standard immediate-release tablet.
This creates an unusual market structure. Entry is legally open, but sustained supply is commercially fragile.
Is there biosimilar risk for Serzone?
There is no biosimilar risk because nefazodone is a conventional small-molecule drug. The relevant competitors are generic tablets approved through the abbreviated new drug application pathway, not biosimilars approved under the Public Health Service Act.
The competitive risks are therefore:
- Generic substitution.
- Manufacturer withdrawal.
- Supply interruption.
- Patient migration to alternative antidepressants.
- Re-entry by a low-cost manufacturer if demand rises.
Did Bristol-Myers Squibb license Serzone?
Serzone was primarily a Bristol-Myers Squibb product. Its commercial history does not indicate a current licensing structure that generates material revenue for the original sponsor.
Any historical development, distribution, or international commercialization arrangements would have limited relevance after the U.S. brand withdrawal. The economic value of the asset was largely extinguished by declining prescriptions, safety warnings, and generic competition.
How does Serzone compare with competing antidepressants?
Serzone had a narrower commercial profile than leading SSRIs and SNRIs because its safety warning affected a potentially fatal organ toxicity risk.
| Factor |
Serzone / nefazodone |
SSRIs |
SNRIs |
| Market position |
Niche and largely discontinued |
Broad |
Broad |
| Generic competition |
High |
High |
High |
| Major safety concern |
Severe hepatotoxicity |
Varies by product |
Varies by product |
| Brand economics |
Ended in the U.S. |
Mostly generic after patent expiry |
Mostly generic after patent expiry |
| Physician adoption |
Restricted |
Established |
Established |
| Regulatory burden |
Liver-risk monitoring and warning |
Product-specific |
Product-specific |
Nefazodone retained potential clinical differentiation through its pharmacology and lower rates of certain serotonergic adverse effects, but those advantages did not offset the liver-failure risk in routine prescribing.
What is the commercial outlook for nefazodone?
The commercial outlook is limited and defensive. Nefazodone is unlikely to regain a branded antidepressant market without a major change in its safety profile, formulation, indication, or clinical positioning. No such change is evident in the established regulatory record.
Revenue opportunities are concentrated in low-volume generic supply, not branded promotion. A manufacturer could potentially benefit from limited competition if it maintains reliable supply, but pricing power would remain constrained by generic substitution and therapeutic alternatives.
What could cause a generic nefazodone shortage?
A shortage could result from:
- Withdrawal of one of the few active manufacturers.
- API sourcing problems.
- Low production volumes.
- Quality-control findings.
- Unfavorable manufacturing economics.
- Distribution decisions by wholesalers or pharmacies.
A shortage could increase short-term prices without improving the long-term franchise value. The patient population is small, and many prescribers can switch patients to alternative antidepressants.
What is the geographic coverage of Serzone and nefazodone?
The United States is the most important historical market because FDA regulatory actions and Bristol-Myers Squibb’s withdrawal decision shaped the product’s global reputation. Availability outside the United States has varied by country, with some markets using nefazodone under generic or local brand names and others withdrawing or limiting it.
| Region |
Market position |
| United States |
Brand withdrawn; limited generic availability |
| Canada |
Historical availability, with market status subject to local authorization |
| Europe |
Limited and country-specific availability |
| Other markets |
Generic or local-brand access varies |
The regulatory status must be assessed country by country. A product can remain authorized in one jurisdiction while being withdrawn, unavailable, or commercially inactive in another.
Key Takeaways
- Serzone is the former U.S. brand name for nefazodone.
- Bristol-Myers Squibb launched Serzone in 1994 and discontinued U.S. marketing in 2004.
- The principal cause of commercial failure was severe hepatotoxicity and the FDA boxed warning for potentially fatal liver failure.
- Generic nefazodone entered after the original exclusivity period, but current supply is limited and commercially fragile.
- The original patent estate has no meaningful present-day ability to block generic competition.
- No biosimilar pathway applies because nefazodone is a small-molecule drug.
- Current value lies in low-volume generic supply, not in branded sales, licensing, or patent enforcement.
- The main commercial risks are liability, limited demand, manufacturing economics, and possible supply interruption.
FAQs About Serzone and Nefazodone
Is Serzone still sold in the United States?
The Serzone brand is not actively marketed in the United States. Generic nefazodone may be available through limited manufacturers and pharmacy channels.
Why was Serzone discontinued?
Bristol-Myers Squibb discontinued U.S. marketing because sales declined after reports of severe liver injury and FDA-required warnings. The company did not withdraw the product because the FDA issued a mandatory market-removal order.
Can nefazodone still be prescribed?
Yes. Generic nefazodone remains an FDA-approved antidepressant, but prescribers must consider the boxed warning and avoid use in patients with active liver disease or elevated baseline liver enzymes.
Does nefazodone have any remaining patent protection?
No meaningful original patent or regulatory exclusivity appears to block generic competition in the United States. The current market is governed by generic approval, product availability, and safety labeling.
Is nefazodone more commercially attractive than newer antidepressants?
No. Nefazodone has low commercial attractiveness because of limited demand, a serious liver-safety warning, generic pricing pressure, and liability exposure. Newer branded antidepressants with differentiated mechanisms or formulations generally have stronger commercial potential.
References
- U.S. Food and Drug Administration. (2001). FDA public health advisory: nefazodone hydrochloride.
- Bristol-Myers Squibb Company. (2003). Serzone U.S. marketing discontinuation announcement.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- U.S. Food and Drug Administration. (2023). Nefazodone hydrochloride prescribing information. DailyMed.
- U.S. Food and Drug Administration. (2002). Nefazodone and risk of hepatotoxicity: labeling and safety communications.
